The balance between activating and inhibitory signals from the different FcgRs for IgG ensures homeostasis of many inflammatory responses. FCGR2C is the product of an unequal crossover of the FCGR2A and FCGR2B genes encoding the activating FcgRIIa (CD32a) and inhibitory FcgRIIb (CD32b), respectively. A single nucleotide polymorphism (SNP) in exon 3 of FCGR2C results in either expression of the activating FcgRIIc (CD32c) (FCGR2C-open reading frame [ORF] ) or its absence because of a stop codon (FCGR2C-Stop). Two additional variations in FcgRIIb/c expression on leukocytes have now been identified. In case of "nonclassical" FCGR2C-ORF alleles, FcgRIIc expression was unexpectedly absent, because of novel splice site mutations near exon 7 leading to another stop codon. In some individuals with FCGR2C-Stop alleles FcgRIIb was detected on NK cells, which normally are devoid of this protein. Individuals with these nonclassical FCGR2C-Stop alleles carried a deletion of FCGR2C-FCGR3B that extends into the promoter region of the adjacent FCGR2B gene and probably deletes a negative regulatory element in the FCGR2B promoter in NK cells. FcgRIIb expression on NK cells effectively inhibited killing mediated by FcgRIIIa (CD16a) in Ab-dependent cytotoxicity tests. Our findings demonstrate a more extensive and previously unnoticed variation in FcgR expression with relevance to immunity and inflammation. The Journal of Immunology, 2012, 188: 1318-1324. (1) . Depending on their affinity for IgG, the receptors can be divided into low-affinity FcgRs, which can be subdivided into FcgRIIa (CD32a), FcgRIIb (CD32b), FcgRIIc (CD32c), FcgRIIIa (CD16a), and FcgRIIIb (CD16b), and the high-affinity FcgRI (CD64). In humans, FcgRIIb is the only inhibitory FcgR, because it contains an ITIM in its cytoplasmic tail. All other FcgRs signal through an ITAM, either encoded within their cytoplasmic tail or within associated adaptor proteins such as the FcRg.
The genes encoding the FcgRs are located on chromosome 1, of which the genes FCGR2A, FCGR2B, and FCGR2C are located in one gene cluster with the FCGR3A and FCGR3B genes.
Because of the very high homology between the genes, it is a difficult gene cluster to study. For instance, FCGR2A and FCGR2B have ∼95% homology in their exons coding for the extracellular domains of FcgRIIa and FcgRIIb, respectively (2) . The activating FcgRIIa is expressed by neutrophils, monocytes, macrophages, dendritic cells, and platelets, in which it mediates various functions such as phagocytosis and Ab-dependent cellular cytotoxicity (ADCC). The inhibitory FcgRIIb exists in two splice variants, namely, FcgRIIb1 (which is exclusively expressed by B cells) and FcgRIIb2 (expressed by B cells, macrophages, and dendritic cells). FcgRIIb inhibits signaling of ITAM-associated receptors by recruitment of phosphotyrosine phosphatases that dephosphorylate the tyrosine residues in several ITAM-induced activation pathway effectors (3) .
Single nucleotide polymorphisms (SNPs) have been described in both FCGR2A and FCGR2B. A functionally relevant SNP in FCGR2A leads to either a histidine or an arginine in the ligandbinding domain of FcgRIIa (H/R131) (4). This results in differences in binding affinity for human IgG 2 and murine IgG 1 (4, 5) . In FCGR2B, one SNP leads to either an isoleucine or a threonine in the transmembrane region of FcgRIIb (I/T232). The T232 allotype has been suggested to result in functional impairment through exclusion from lipid rafts (6, 7) . Additional SNPs in the promoter region influence transcriptional activity of FCGR2B (and FCGR2C) (8, 9) . FCGR2C, encoding FcgRIIc, appears to be the product of an unequal crossover event between FCGR2A and FCGR2B (10). FCGR2C contains eight exons, which are highly homologous to exons 1-4 from FCGR2B and exons 5-8 from FCGR2A. An SNP in exon 3 of FCGR2C determines the functional expression of this gene. This SNP results in either an open reading frame (FCGR2C-ORF) or the more common stop codon (FCGR2C-Stop), in which case FCGR2C represents a pseudogene (11) . FcgRIIc is expressed on NK cells from FCGR2C-ORF donors, acting as an activating IgG receptor capable of inducing ADCC and a rise in Ca 2+ concentration after receptor crosslinking (12, 13).
Differences in receptor expression levels on the cell surface can alter the balance between activating and inhibitory signals and therefore change the cellular response toward IgG. Apart from SNPs, we and others have shown that several FCGR genes are subject to copy number variation (CNV). CNV in FCGR2C, FCGR3A, and FCGR3B has been shown to correlate with protein expression levels. For instance, deletion of one FCGR3A allele results in reduced target cell killing in an FcgRIIIa-specific ADCC (14) . These SNPs and CNVs in FCGR genes have been linked with (chronic) inflammatory and autoimmune diseases (12, 15) . It is therefore essential to further investigate genetic variation in this gene cluster, because that may be highly relevant for the discovery of disease risk factors, therapeutic efficacy of biologicals, and the development of new treatment strategies. In this study, we identify two additional genetic variations in the FCGR gene cluster that modulate the expression of FcgRIIb and FcgRIIc.
Materials and Methods

Subjects
Healthy adult white volunteers (n = 146) served as controls. These donors were not known to have hematological disorders of any kind in the past or at present. The study was approved by the Medical Ethics Committee of the Academic Medical Center and Sanquin (Amsterdam, The Netherlands) and was performed in accordance with the Declaration of Helsinki.
Abs and reagents
The following mAbs were used in flow cytometry and for immunopre- IP lysis buffer is PBS containing 10% glycerol (w/v), 1% Nonidet P-40 (w/v), and 13 Complete, EDTA-free Protease Inhibitor Mixture (Roche Applied Science, Almere, The Netherlands). Laemmli sample buffer is 50 mM Tris-HCl (pH 6.8), 10% glycerol (v/v), 5 mM DTT (DL-DTT; Sigma-Aldrich), 1% 2-ME, 1% SDS (w/v), and 100 mg/ml bromephenol blue. Complete medium is IMDM (PAA, Pasching, Austria) supplemented with 10% FCS(v/v) (Bodinco, Alkmaar, The Netherlands), penicillin (100 U/ml), streptomycin (100 mg/ml; PAA), and 2 mM Lglutamine (PAA).
Genotyping
Genomic DNA was isolated from whole blood with the Gentra Puregene kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions.
CNV and SNPs in the low-affinity FCGR genes FCGR2A, FCGR2B, FCGR2C, FCGR3A, and FCGR3B were determined with an FCGR-specific multiplex ligation-dependent probe amplification (MLPA) assay. The MLPA assay was performed essentially as described previously (12, 17) . The FCGR MLPA includes gene-specific probes to determine the CNV of the genes. It also includes probes to detect the following SNPs:
, and FCGR3B (HNA1a/HNA1b/HNA1c). The assay also contains a probe specific for the open reading frame in exon 3 of the FCGR2C gene and a nonspecific FCGR2B/C probe to detect the stop codon in exon 3. For selected donors, we designed and used probes to determine the extent of the FCGR2C/FCGR3B deletion. Probe sequences are 59-GGGTTCCCTAAGGGTTGGAGAAGCATGACTCTTCTAAAAC-AAGTTAATAAT-39 and 59-AATGACATCTTTTCATGAACAAGCAATTG-AGTCTAGATTGGATCTTGCTGGCAC-39 for the region between FCGR3A and FCGR2C and 59-GGGTTCCCTAAGGGTTGGACACCATCTCAGTA-GTAATTTCTGACACATCACTTT-39 and 59-CAGAAGGCTCATAAGCC-AACTCAGATACAACCGTCTAGATTGGATCTTGCTGGCGC-39 for the region between FCGR3B and FCGR2B.
PCR and sequence analysis
Quantitative PCR analysis and sequencing of FcgRIIc transcripts, as well as the gene-specific, long-range PCR analysis and sequencing of FCGR2C, were performed as described previously (12) .
NK cell purification
PBMCs were isolated from whole blood by Percoll density gradient centrifugation. NK cells were isolated from PBMCs by MACS with CD56 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany), following the manufacturer's instructions. NK cell purity was verified by flow cytometry.
mRNA isolation and reverse transcription mRNA was isolated from 1 3 10 6 purified NK cells by use of the QiaAmp RNA blood mini kit (Qiagen), according to the manufacturer's instructions. Subsequently, first-strand cDNA was synthesized with the Superscript III first-strand synthesis system for RT-PCR (Invitrogen, Breda, The Netherlands). In short, RNA was primed with 2.5 mM oligo(dT) for 5 min at 65˚C. Reverse transcription was performed with 10 U/ml Superscript III in the presence of 5 mM MgCl 2 , 20 mM Tris-HCl, 50 mM KCl (pH 8.4, reverse transcriptase buffer), 0.5 mM 29-deoxynucleoside 59-triphosphate, and 2 U/ml RNaseOUT [without DTT, for reasons described by Lekanne Deprez et al. (18)] for 50 min at 50˚C. Thereafter, Superscript III was inactivated by incubation for 5 min at 85˚C, followed by chilling on ice. Immediately thereafter, 2 U RNase H were added, and the mixture was incubated at 37˚C for 20 min. Subsequently, cDNA was stored at 20˚C until further use.
Detection and relative quantification of FcgRII isoform-specific mRNA
The detection and relative quantification of FcgRII mRNA have been described in detail elsewhere (19) . In short, intron-spanning primers were designed to specifically amplify cDNA and exclude amplification of genomic DNA, yielding products of 100 bp for b-glucuronidase (GUS), 243 bp for FcgRIIb2, and 162 bp for FcgRIIc1 as the most abundant productive FcgRIIc transcript in immune cells (12) . The following primers were used: b-glucuronidase (GUS), 59-GAAAATATGTGGTTGGAGAGCTCATT-39 (forward primer) and 59-CCGAGTGAAGATCCCCTTTTTA-39 (reverse primer); FcgRIIb2, 59-GGAAAAAGCGCATTTGAGCCAATC-39 (forward primer) and 59-GGAAATACGAGATCTTCCCTCTCTG-39 (reverse primer); and FcgRIIc1, 59-ATCATTGTGGCTGTGGTCACTGG-39 (forward primer) and 59-CTTTCTGATGGCAATCATTTGACG-39 (reverse primer). Quantification of cDNA was performed with the Lightcycler Instrument (Roche Applied Science). Serial 10-fold dilutions of the cDNA were made and quantified with the method described in Technical Note No. LC 13/2001 (Roche Applied Science).
IP and Western blotting of FcgRII
IP was performed at 4˚C. Cells were pretreated with 10 mM diisopropyl fluorophosphate for 10 min and lysed with IP lysis buffer for 1 h. Lysates were centrifuged at 21,000 3 g for 15 min. Supernatants were incubated with pan-FcgRII Abs (10 mg/ml) overnight. Subsequently, they were incubated with 5% protein G-Sepharose 4 Fast Flow (w/v) (GE Healthcare Life Sciences) for 1 h. Protein G-Sepharose was washed three times with IP lysis buffer by centrifugation at 21,000 3 g for 15 s and incubated in Laemmli sample buffer for 30 min at 95˚C.
Samples were run on a 12.5% Bis-Tris gel (w/v) and subsequently blotted on a nitrocellulose membrane. FcgRIIb and -c were detected by polyclonal Abs against their cytoplasmic tails. Bands were visualized by ECL substrate (Pierce, Rockford, IL).
Cytotoxicity assays
Cytotoxicity of NK cells was determined by Ab-dependent cellular cytotoxicity (ADCC) and redirected ADCC (rADCC). NK cells were isolated from FCGR2C-ORF, FCGR2C-Stop, and nonclassical FCGR2C-Stop donors and kept in complete medium. Target cells were labeled with 51 Cr for 1 h and subsequently washed three times. Cells were plated in a 96-well plate at 5 3 10 3 cells/well. NK cells were added at varying E:T cell ratios and incubated in triplicate. In case of ADCC, chimeric therapeutic mAbs against CD20 (rituximab) were added at 10 mg/ml. In case of rADCC, mouse mAbs against either human FcgRII or human FcgRIII were added at 10 mg/ml. As a control, target and NK cells were plated without Abs. Target cells were also plated without NK cells to determine the spontaneous release or with saponine to determine the maximum release of 51 Cr. The total volume per well was 100 ml. Cells were centrifuged at 300 3 g for 30 s and subsequently incubated at 37˚C and 5% CO 2 for 4 h. Cells
Specific killing was determined by the formula: percentage specific killing = 100 3 (experimental release 2 spontaneous release)/(maximum release 2 spontaneous release).
Statistics
Flow cytometry data were analyzed with Student t test; p , 0.05 was considered statistically significant. Data are expressed as mean 6 SEM.
Results
Mismatches between FCGR2C genotype and phenotype
We have analyzed the FcgR expression by genotyping CNV and SNPs within the FCGR2A, FCGR2B, FCGR2C, FCGR3A, and FCGR3B genes by MLPA in 146 healthy adult white individuals (Tables I, II ; data not shown) and phenotyping a selection of 47 of these individuals with different mAbs against FcgRII (pan-CD32), FcgRIIb/c (CD32b/c), and FcgRIIIa/b (CD16).
There is no mAb available that can differentiate between surfaceexpressed FcgRIIb and FcgRIIc because of the completely identical extracellular domains. NK cells express FcgRIIc but not FcgRIIb (12) , and these cells can therefore be used to distinguish FCGR2C-Stop from FCGR2C-ORF donors at the level of surface expression with a FcgRIIb/c-specific mAb.
When we related the genotype for FCGR2C with the FcgRIIc expression on NK cells as measured by flow cytometry (Fig. 1) , we observed a strong and positive correlation between genotype and average protein surface expression levels. However, we also detected two exclusive sets of individuals that showed definite genotype-phenotype mismatches. First, we identified individuals who repeatedly showed no FcgRIIb/c surface expression on NK cells in the presence of a classical FCGR2C-ORF genotype (group A). Second, we identified some individuals whose NK cells were stained for FcgRIIb/c while carrying classical FCGR2C-Stop alleles, considered to be true pseudogenes (group B). Expression of FcgRIIc is known to be determined by the p.Q13X (ORF versus Stop) mutation in exon 3 of the FCGR2C gene. Interestingly, NK cells of some of the FCGR2C-ORF donors did not express FcgRIIc. The lack of expression was not limited to NK cells but was also apparent on myeloid cells, as indicated for monocytes and neutrophils ( Fig. 2A) . To investigate whether RNA transcripts for FcgRIIc were detected in the PBMC fraction of nonclassical FCGR2C-ORF donors, PCR analysis was performed on the RNA from three donors. Sequence analysis of the PCR products revealed various FcgRIIc transcripts. Most abundantly, we found transcripts from which exon 7 was spliced out. In two of these donors, the transcripts contained in addition a 62-bp insertion, which was found to be part of intron 7 (Fig. 2B) . Both unusual transcripts result in a frameshift and premature stop codon. Exon 6 was spliced out from all transcripts but that is normal for myeloid cells from all FCGR2C-ORF donors. The only isoform of FcgRII in which exon 6 is not spliced out is the B cell-specific FcgRIIb1. Besides these most commonly found transcripts in the three nonclassical FCGR2C-ORF donors, additional noncoding transcripts were detected as well. Premature stop codons can result in various nonsense mRNAs. It is likely that these less frequently found transcripts fall in this category. In normal FCGR2C-ORF donors, these noncoding transcripts were not detected (data not shown).
A gene-specific, long-range PCR was performed to amplify FCGR2C from genomic DNA. Sequence analysis of the PCR product revealed that all three nonclassical FCGR2C-ORF donors studied thus far carried a G→A point mutation at the donor splice site of intron 7, which explains a splicing defect that results in the loss of exon 7. In addition to this mutation, two donors also had a G→C point mutation at the acceptor splice site of intron 7. In these donors, a cryptic acceptor splice site 62 bp upstream of the normal exon-intron boundary was used, which explains the insertion of part of intron 7 in these two donors (Fig. 2C) .
Nonclassical FCGR2C-Stop because of gene deletions in the FCGR cluster (group B)
Because FCGR2C-Stop donors are expected to be unable to express any isoform of FcgRII on NK cells, we were surprised to find that the NK cells from some of these healthy individuals did bind mAb 2B6, which is specific for FcgRIIb and FcgRIIc. Although genotyping errors in FCGR2C were considered, there was an important phenotypic difference with the binding pattern with the same mAb on immune cells from individuals carrying classical FCGR2C-ORF (Fig. 3A) . Neutrophils and monocytes from these four individuals from group B showed a similar lack of surface Further studies of these donors in which the NK cells unexpectedly showed CD32b/c surface expression were performed at the genomic level. MLPA analysis of DNA from these so-called nonclassical FCGR2C-Stop donors showed that these individuals all carried a large deletion in the FCGR locus, resulting in the combined loss of both FCGR2C and FCGR3B on one of their alleles (14) . MLPA probes were designed to analyze the regions located around these genes to investigate the extent of this deletion. The deletion of FCGR2C and FCGR3B was found to include part of the sequence between the FCGR3B gene and the presumed promoter region of the FCGR2B gene (Fig. 3B) .
We hypothesized that a regulatory element in this region could be involved in repression of FcgRIIb expression and that deletion of this element results in FcgRIIb expression on NK cells. Therefore, RNA was isolated from NK cells from individuals genotyped and phenotyped as FCGR2C-ORF, FCGR2C-Stop, and nonclassical FCGR2C-Stop (group B) donors. FcgRIIb1 mRNA was not detectable in NK cells, but some FcgRIIb2 mRNA was found to be present in NK cells of all individuals. In subsequent quantitative PCR experiments, the relative amounts of FcgRIIb2 and the major FcgRIIc (FcgRIIc1) mRNA were determined, compared with a household gene. Upon comparison of FCGR2C-ORF and -Stop donors, the nonclassical FCGR2C-Stop donors showed strongly increased transcriptional levels of FcgRIIb2 mRNA. FcgRIIc1 mRNA was comparable between classical and nonclassical FCGR2C-Stop and was-as expected-strongly elevated in the FCGR2C-ORF donors (Fig. 3C) .
This led to the hypothesis that FcgRIIb and not FcgRIIc is expressed on the NK cells of these nonclassical FCGR2C-Stop donors. The assumption was further verified at the protein level. IPs of FcgRII with pan-FcgRII mAb AT10 were performed from lysates of highly purified NK cell fractions obtained from individuals with the FCGR2C-ORF, -Stop, and nonclassical Stop signature after combined geno-/phenotyping. These immunoprecipitates were used for Western blotting and stained with Abs specific for the intracellular tail of either FcgRIIa/FcgRIIc (data not shown) or FcgRIIb (Fig. 3D) . The experiments confirmed that NK cells from nonclassical FCGR2C-Stop donors indeed express FcgRIIb as the single FcgRII.
To test whether expression of FcgRIIb on NK cells had functional consequences, cytotoxicity was tested in rADCC assays (Fig. 4) . Killing of target cells in the presence of mAbs for FcgRIII was comparable between NK cells from all donor types. As we had also previously published (11, 12) , NK cells from FCGR2C-ORF donors were able to kill target cells in the presence of mAbs for FcgRII, whereas NK cells from FCGR2C-Stop donors, not able to bind these mAbs, were unable to kill under these rADCC conditions (Fig. 4A) . As expected, NK cells from nonclassical FCGR2C-Stop donors, expressing the inhibitory FcgRIIb, were not able to kill target cells in the presence of mAbs for FcgRII (Fig. 4B) . Rare individuals carrying both an FCGR2C-ORF allele and a nonclassical FCGR2C-Stop allele will express both FcgRIIb and FcgRIIc on NK cells. We had identified a healthy donor with this genotype. The NK cells from this individual were unable to kill the target cells in the rADCC, despite expression of FcgRIIc. Thus, FcgRIIb on NK cells is unable to mediate cytotoxicity, but effectively inhibits killing mediated through FcgRIIc when coexpressed and ligated in the rADCC test system (Fig. 4B) .
Because NK cells also express FcgRIIIa, the effect of FcgRIIb and FcgRIIc expression on cytotoxicity was tested in a classical ADCC test in which the clinically applied chimeric CD20 mAb rituximab was used to opsonize the Raji B cell lymphoma cell line as target cell. In these experiments, we observed that the expression of FcgRIIb on the NK cells of nonclassical FCGR2C-Stop donors resulted in decreased NK cell-mediated killing of the Raji target cells when preincubated with the CD20 mAb (Fig. 4C) .
Discussion
Expression of FcgR on NK cells is normally limited to the activating FcgRIIIa (CD16a). We and others (12, 13) have previously shown that NK cells from ∼20% of healthy individuals express Classically, an SNP in exon 3 of the gene encoding for FcgRIIc determines whether a stop codon in exon 3 or an ORF is present. However, in a number of healthy individuals, genotyping of FCGR2C by the SNP in exon 3 alone is insufficient. Additional mutations at the splice sites of intron 7 in their FCGR2C-ORF alleles were shown to exist, resulting in another stop codon. Although our previous study on FCGR2C-ORF in ITP (12) has become even more significant because of the lower frequency of nonclassical FCGR2C-ORF patients with ITP compared with the healthy control population (data not shown), nonclassical FCGR2C-ORF alleles may lead to the misinterpretation of cohort studies when only analyzed for the typical FCGR2C-ORF exon 3 alleles. Future experiments should include analysis of the intron 7 splice sites to determine the number of classical FCGR2C-ORF donors. We have found that ∼20% of the FCGR2C-ORF donors from our cohort of healthy white adults carry nonclassical FCGR2C-ORF alleles and are not expressing any FcgRIIc. From the phenotypic point of view, nonclassical FCGR2C-ORF donors should be included in the FCGR2C-Stop group because FcgRIIc is not expressed in these donors.
We have also shown in this study that some individuals express FcgRIIb on all circulating NK cells, which normally do not show any FcgRIIb expression. Although indications for this phenomenon have been reported before, this was not further explored (13, 20) . We have now identified that such donors have a deletion at the FCGR locus that includes FCGR2C, FCGR3B, and part of the region between FCGR3B and FCGR2B. The prevalence of such deletions among healthy white individuals is ∼3%, but another racial background may result in a different prevalence. Our data suggest that deletion of one or more inhibitory elements in the 30-kb DNA sequence between the FCGR3B and the FCGR2B genes results in the unusual expression of FcgRIIb on NK cells. In these individuals, the B cell expression of FcgRIIb is unaltered, and the circulating neutrophils and monocytes do not show the FcgRIIb expression, as we demonstrated by flow cytometry and IP (Fig. 3) . The fact that these donors do not show (increased) expression of FcgRIIb on other tested immune cells may indicate that this regulatory element normally acts to selectively suppress the FcgRIIb expression in NK cells.
Because of the inhibitory nature of FcgRIIb (13, 21) , the NK cell expression of FcgRIIb is presumed to result in a reduction in Taken together, we have identified several novel genetic variations in the FcgRII/III locus, thereby demonstrating that the degree of genetic variation within this locus is considerably larger than determined previously. Apart from its natural cytotoxic activity toward tumors and viral infections, evidence for a regulatory role of NK cells in inflammation and infectious disease has accumulated during the past decade (22) (23) (24) (25) (26) (27) . It will be of interest to see whether the presence of FcgRIIb is linked to the susceptibility for cancer and inflammatory diseases.
Clearly, a more accurate FcgR genotyping, including the currently described variants, will be useful for improving our understanding of the role of FcgR in disease.
